Demographics and cystic fibrosis (CF) therapies in 24 adults with CF at baseline (prior to commencement of lumacaftor/ivacaftor)
| Male | 54.2 |
| Age years | 32.6±8.6 |
| Height cm | 169.0±10.4 |
| BMI kg·m−2 | 20.3±2.7 |
| FEV1 L | 1.30±0.41 |
| FEV1 % pred | 34.7±7.4 |
| FVC L | 2.65±0.81 |
| FVC % pred | 57.8±10.0 |
| FEF25–75% L | 0.51±0.19 |
| FEF25–75% % pred | 13.3±4.2 |
| Diagnosis of CF-related diabetes mellitus | 33.3 |
| Diagnosis of CF-related liver disease | 33.3 |
| Use of supplementary oxygen therapy | 0.0 |
| Azithromycin | 87.5 |
| Recombinant human DNase | 58.3 |
| Hypertonic saline | 58.3 |
| Inhaled antibiotics | 41.4 |
| Oral antibiotics | 33.3 |
| Inhaled corticosteroids | 87.5 |
| Oral corticosteroids | 4.2 |
| Long-acting β2-agonists | 91.7 |
| Long-acting muscarinic antagonists | 4.2 |
Data are presented as % or mean±sd. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF25–75%: forced expiratory flow at 25–75% of FVC.